Saniona Logo

Saniona

SANION | ST

Overview

Corporate Details

ISIN(s):
SE0005794617 (+1 more)
LEI:
549300XO4L9XNOCFCZ84
Country:
Denmark
Address:
Smedeland 26 B, 2600 GLOSTRUP
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Saniona is a clinical-stage biopharmaceutical company specializing in the discovery and development of medicines for epilepsy and other neurological disorders. A pioneer in ion channel research, the company leverages its deep expertise in highly specific ion channel modulation to advance its pipeline. Saniona operates a proprietary drug discovery engine and has generated a library of over 20,000 proprietary molecules to identify and develop innovative therapies. The company is focused on advancing multiple potential new medicines through clinical trials with the mission of improving the lives of patients.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Saniona. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-28 08:00
Interim Report
Swedish 1.2 MB
2025-08-28 08:00
Interim Report
English 1.1 MB
2025-08-20 13:30
M&A Activity
Saniona ingår exklusivt licensavtal med Jazz Pharmaceuticals för att utveckla o…
Swedish 232.7 KB
2025-08-20 13:30
M&A Activity
Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Devel…
English 233.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Saniona AB
Swedish 151.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Saniona AB
English 150.7 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S requests conversion of the remaining outstanding convertib…
English 146.1 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av resterande utestående konvertible…
Swedish 146.6 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Kommuniké från årsstämma den 28 maj 2025 i Saniona AB
Swedish 216.1 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Bulletin from the Saniona AB annual shareholders’ meeting on May 28, 2025
English 216.0 KB
2025-05-28 08:00
Earnings Release
Swedish 1.2 MB
2025-05-28 08:00
Investor Presentation
English 1.1 MB
2025-05-12 08:00
Board/Management Information
Saniona utser Johnny Stilou till Chief Financial Officer
Swedish 210.3 KB
2025-05-12 08:00
Board/Management Information
Saniona appoints Johnny Stilou as Chief Financial Officer
English 209.6 KB
2025-04-30 12:10
Annual Report (ESEF)
Swedish 1.8 MB

Automate Your Workflow. Get a real-time feed of all Saniona filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Saniona via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-01 Thomas Feldthus Other Other 220,000 1,073,600.00 SEK
2025-04-01 Pierandrea Muglia Other Other 53,333 260,265.04 SEK
2025-04-01 Thomas Feldthus Other Other 30,000 146,400.00 SEK
2024-10-02 John Haurum Other Buy 67,100 60,363.16 SEK
2024-10-02 John Haurum Other Buy 12,361 51,415.58 SEK
2024-01-29 Pierandrea Muglia Other Other 53,333 219,731.96 SEK
2022-07-05 Karl Johan Bertil Sundberg Other Buy 40,000 142,128.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 130,590.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 129,600.00 SEK
2022-07-05 Thomas Feldthus Other Buy 5,221 22,685.24 SEK

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN